Melissa Boneta Davis

This study shows mutant p53 uses its C-terminal domain to reprogram PARP activity, enabling replication stress adaptation and metastasis in TNBC, and identifies mtp53 as a biomarker for PARP inhibitor and DNA-damaging therapy.

This paper introduces an explainable boosting machine model to identify and filter variant artifacts caused by formalin-fixed paraffin embedding in cancer genomics.

The paper identifies African Pan Genome contigs that are missing from current human reference genomes, showing they contain functionally relevant sequences and are enriched in African ancestry.

This study develops a pan-cancer PDO platform to preserve tumor heterogeneity and identify therapeutic vulnerabilities, finding that 58% of PDOs respond to Talazoparib and combination screens reveal resistance-overcoming drugs.

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

This study analyzes whole-exome sequencing data from Nigerian prostate cancer tumors to identify germline and somatic variants associated with African ancestry and DNA repair gene mutations.